Document Type
Article
Publication Date
6-14-2024
ISSN
2666-5247
Publisher
Elsevier
Language
en-US
Abstract
In June, 2023, the Council of the EU published a recommendation that the European Commission should contribute to the design and governance of an EU cross-country pull incentive to stimulate antimicrobial innovation and access. In this Personal View, we discuss six key considerations to support the implementation of the new pull incentive—ie, the size of the potential pull incentive and possible contributions of the member states, design of the incentive model, interplay of the new pull incentive with the proposed revisions of the EU pharmaceutical legislation, roles and responsibilities of both the EU and member states, balance between pull and push incentives, and global cooperation and responsibility. As the involvement of the member states with the EU pull incentive will be voluntary, member states should have confidence that the processes used to identify eligible antimicrobials, negotiate terms and conditions, and oversee access agreements are transparent, inclusive, and methodologically robust.
Recommended Citation
Michael Anderson, Adrian Towse, Kevin Outterson & Elias Mossialos,
Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action
,
in
Online First
The Lancet: Microbe
(2024).
Available at:
https://doi.org/https://doi.org/10.1016/S2666-5247(24)00109-5
